1. Miller WL. Molecular biology of steroid hormone synthesis. Endocr Rev 9:295-318, 1988.
2. Chung B, Matteson KJ, Votilainen R, et al. Human cholesterol side-chain cleavage enzyme, 450scc: cDNA cloning, assignment of the gene to chromosome 15 and expression in the placenta. Proc Natl AcadSci USA 83:8962-8966, 1986.
3. Kominami S, Ochi H, Kobayashi T, et al. Studies on the steroid hydroxylation system in the adrenal cortex microsomes: purification and characterization of the cytochrome P450 specific for steroid 21 hydroxylation. J Biol Chem 255:3386-3394, 1980.
4. White PC, Chaplin DD, Weis JH, et al. Two steroid 21-hydroxylasegenes are located in the murine S region. Nature 312:465-467, 1984.
5. White PC, New MI, Dupont B. HLA-linked congenital adrenal hyperplasia result from a defective gene encoding a cytochrome P450 specific for steroid 21-hydroxylation. Proc Natl AcadSci USA 81:7505-7509, 1973.
6. Curnow KM, Tusie-Luna MT, Pascoe L, et al. The product of CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex. Mol Endocrinol 5:1513-1522, 1991.
7. Chua SC, Szabo P, Vitek A, et al. Cloning of cDNA encoding steroid 11?-hydoxylase (P450c11). Proc Natl AcadSci USA 84:7193-7197, 1987.
8. Mornet E, Dupont J, Vitek A, et al. Characterization of two genes encoding human steroid 11?-hyroxylase (P450(11)?). J Biol Chem 264:20961-20967, 1989.
9. Gibbons GH, Dzau VJ, Farhl ER, et al. Interaction of signals influencing renin release. Ann Rev Physiol 46:291-08, 1984.
10. Williams GH, Durhy RG. Regulation of aldosterone secretion. In: Genest J, Künchel O, Hamet P, et al. Eds. Hypertension: Physiology and Treatment. 2nd ed. New York.McGraw-Hill, pp320-327, 1983.
11. Quinn SJ, Williams GH. Regulation of aldosterone secretion. Ann Rev Physiol 50:409-429, 1988.
12. Fujita K, Aguilera G, Vatt KJ. The rile of cyclic AMP on aldosterone production by isolated zona glomerulosa. J Biol Chem 254:8567-8574, 1979.
13. Kramer RE, Gallant S, Brownie AC. Action of angiotensin II on aldosterone biosynthesis in the rat adrenal coretex. J Biol Chem 255:3442-3447, 1980.
14. McKenna TJ, Island DP, Nicholson WE, et al. The effects of potassium on early and late step om aldosterone biosynthesis in cells of the zona glpmerulpsa. Endocrinology 103:1411-1416, 1978.
15. Kojima I, Kojima K, Rasmussen H. Role of calcium and cANP in the action of adrenocorticotropin on aldosterone secretion. J Biol Chem 269:4248-4256, 1985.
16. Woodcock EA, McLeod JK, Johnston CI. Vasopressin stimulates phosphatidylinositol turnover and aldosterone synthesis in rat adrenal glomerulosa cells: comparison with angiotensin II. Endocrinology 118:2432-2436, 1986.
17. Hollenberg NK, Chenitz WR, Adams DF, et al. Reciprocal influence of salt intake on adrenal glomerulosa and vascular response to angiotensin II in normal man. J Cin Invest 54:34-42, 1974.
18. Carey RM. Acute dopaminergic inhibition of aldosterone secretion is independent of angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 54:463-469, 1982.
19. Missale C, Liberini P, Memo M, et al. Characterization of dopamine receptors associated with aldosterone secretion in rat adrenal glomerulosa. Endocrinology 119:2227-2232, 1986.
20. Chartier L, Schiffrin EL. Role of calcium in effects of atrial natriuretic peptide on aldosterone production in adrenal glomerulosa cells. Am J Physiol 252:E485-E491, 1987.
21. Jorgensen PL. Structure, function and regulation of Na, K-ATPase in the kidney. Kidney Intern 20:10-20, 1986.
22. Ikeda U, Hyman R, Smith TW, et al. Aldosterone-mediated regulation of Na+, K+-ATP ase gene expression in adult and neonatal rat cardiocytes. J Biol Chem 266:12058-12066, 1991.
23. Oguchi A, Ikeda U, Kanbe T, et al. Regulation of Na-K-ATP ase gene expression by aldosterone in vascular smooth muscle cells. Am J Physiol 265: H1167-H1172, 1993.
24. Kornel L, Smoszna-Konaszewska B. Aldosterone (ALDO) increase transmembrane influx of Na+ in vascular smooth muscle (VSM) cells through increased synthesis of Na+ channels. Steroids 60:114-119, 1995.
25. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 83:835-839, 1995.
26. Hellal-Levy C, Fagart J, Souque A, et al. Mechanistic aspects of minearlocorticoid receptor activation. Kidney Int 57:1250-1255, 2000.
27. Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human minearlocorticoid receptor complementary DNA: structual and functional kinship with the glucocorticoid receptor. Science 237:268-275, 1987.
28. Fan YS, Eddy RL, Byers MG, et al. The human mineralocorticoid receptor gene (MLR) is located on chromosome 4 at q31.2. Cytogenet Cell Genet 52:83-841989.
29. Morrison N, Harrrap SB, Arriza JL, et al. Regional chromosomal assignment of the human mineralocorticoid receptor gene to 4q31.1. Hum Genet 85:13-132, 1990.
30. Zennaro MC, Keightley MA, Kotelevtsev Y, et al. Human mineralocorticoid receptor genomic structure and identification of expressed isoforms. J Biol Chem 270:21016-21020, 1995.
31. Zennaro MC, Farman N, Bonvalet JP, et al. Tissue-specific expression of ? and ? messenger ribonucleic acid isoforms of the human mineralocoericoid receptor in normal and pathological states. J Clin Endocrinol Metab 82:1345-1352, 1997.
32. Beato M, Sanchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev 17:587-609, 1996.
33. Bamberger CM, Bamberger AM, Wald M, et al. Inhibition of the mineralocoticoid activity by the ?-isoforms of the human glucocorticoid receptor. J Steroid Biochem Molec Biol 63:43-50, 1997.
34. Funder JW, Pearce PT, Myles K, et al. Apparent mineralocorticoid excess, pseudohypoaldosteronism, and urinary electrolyte exertion: toward a redefinition of mineralocorticoid action. FASEB J 4:3234-3238, 1990.
35. Albiston AL, Obeyesekere VR, Smith RE, et al. Cloning and tissue distribution of the human 11?-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 105:R11-R17, 1994.
36. Obeyesekere VR, Li KXZ, Ferrari P, et al. Truncation of the N- and C-terminal regions of the human 11?-hydroxysteroid dehydrogenase type 2 enzyme and effects on solubility and bidirectional enzyme activity. Mol Cell Endocrinol 131:173, 182, 1997.
37. Bujaska I, Shimojo M. Howie A, et al. Human 11?-hydroxysteroid dehydrogenase: studies on the stable transfected isoforms and localization of the type 2 isozyme within renal tissue. Steroids 77:77-82, 1997.
38. Murphy BEP. Specificity of human 11?-hydroxysteroid dehydrogenase. J Steroid Bioche, 14:807-809, 1981.
39. Frey FJ. Kinetics and dynamics of prednisolone. Endocr Rev 8:453-473, 1987.
40. Ferrari P, Smith RE, Funder JW, et al. Substrate and inhibitor specificity of the cloned human 11?-hydroxysteroid dehydrogenase type 2 isoform. Am J Physiol Endocrinol Metab 33:E900-E904, 1996.
41. Souness GW, Morris DJ. The antinatriuretic and kaliuretic effects of the glucocorticoids corticosterone and cortisol following pre-treatment with carbenoxolone sodium (a liquorice derivative) in the adrenalectomized rat. Endocrinology 124:1588-1490, 1989.
42. Canessa CM, Horisberger JD and Rossier BC. Epithelial sodium channel related to proteins involved in neurodegeneration. Nature 361:467-470, 1993.
43. Canessa CM, Schild L, Buell G, et al. Amiloride-sensitive Na+ channel is made of three homologous subunits. Nature 367:463-467, 1994.
44. Volley N, Lingueglia E, Champigny G, et al. The lung amiloride-sensitive Na+ channel. Biophysical properties, pharmacology, ontogenesis, and molecular cloning. Proc Nat Acad Sci USA 91:247-251, 1994.
45. McDonald FJ, Price MP, Synder PM, et al. Cloning and expression of the ?- and ?-subunits of the human epithelial sodium channel. Am J Physiol 268: C1157-C116, 1995.
46. Rotin D, Bar-Sagi D, O'Brodovich H, et al. An SH3 binding region in the epithelial Na+ channel (?ENaC) mediates its localization at the apical membrane. EMBO J 13:4440-4450, 1994.
47. Shimkets RA, Warnock DG, Bositis CM, et al. Liddle's syndrome: Heritable human hypertension caused by mutations in the ? subunits of the epithelial sodium channel. Cell 79:407-414, 1994.
48. Hansson JH, Nelson-Wiliiams C, Suzuki H, et al. Hypertension caused by truncated epithelial sodium channel ? subunit: genetic heterogeneity of Liddle syndrome. Nature Genet 11:76-82, 1995.
49. Hansson JH, Schild L, Lu Y, et al. A de novo missense mutation of the ? subunit of the epithelial sodium channel causes hypertension and Liddle syndrome, identifying a proline-rich segment critical for regulation of channel activity. Proc Natl Acad Sci USA 92:11495-11499, 1995.
50. Tamura H, Schild L, Enomoto N, et al. Liddle disease caused by a missense mutation of ? subunit of the epithelial sodium channel gene. J Clin Invest 97:1780-1784, 1996.
51. Schild L, Lu Y, Schneeberger E, et al. Identification of a PY motif in the epithelial Na channel subunits as target sequence for mutations causing channel activation found in Liddle syndrome. EMBO J 15:2381-2387, 1996.
52. Chang SS, Grunder S, Hanukoguku A, et al. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalemic acidosis, pseudohypoaldosteronism type 1. Nature Genet 12:248-253, 1996.
53. Funder JW, Pearce PT, Myles K, et al. Apparent mineralocorticoid excess, pseudohypoaldosteronism, and urinary electrolyte exertion: toward a redefinition of mineralocorticoid action. FASEB J 4:3234-3238, 1990.
54. Landau RL, Lugibihl K. Inhibition of the sodium-retaining influence of aldosterone by progesterone. J Clin Endocrunol Metab 18:1237-1245, 1958.
55. Hudson JB, Chobanian AV, et al. Hypoaldosteronism. A clinical study of a patient with isolated mineralocorticoid deficiency, resulting in hypokalemia and Strokes-Adama attacks. N Engl J Med 257:529-536, 1957.
56. Schambelan M, Stockight JR, Bigloreli EG. Isolated hypoaldosteronism in adults, a renin-deficiency syndrome. N Engl J Med 287:573-578, 1972.
57. Perez G, Siegel L, Schreiner GE. Selective hypoaldosteronism with hyperkalemia. Ann Intern Med 76:757-763, 1972.
58. Sebastian A, Schambelan M, LindenfeldS, et al. Amelioration of metabolic acidosis with fludrocortisone therapy in hyperreninemic hypoaldosteronism. N Engl J Med 297:576-583, 1977.
59. Perez GO, Lespier L. Jacobi J, et al. Hyporeninemic hypoaldosteronism in diabetes mellitus. Arch Intern Med 137:852-855, 1977.
60. Schembelan M, Sebastian A. Hyporeninemic hypoaldosteronism. Adv Intern Med 24:385-405, 1979.
61. Shaked Y, Blau A, Shipiberg O, et al. Hyporeninemic hypoaldosteronism associated with multiple myeloma: 11 years follow up. Clin Nephrol 40:79-82, 1993.
62. Kiley J, Zager P. Hyporeninemic hypoaldosteronism in two patients with systemic lupus erythematosus. Am J Kidney Dis 4:39-43, 1984.
63. Nakamoto Y, Imai H, Hamanaka S, et al. IgM monoclonal gammopathy accompanied by nodular glomerulosclerosis, urine-concentrating defect, and hyporeninemic hypoaldosteronism. Am J Nephrol 5:53-58, 1985.
64. Escarce JJ. Hyporeninemic hypoaldosteronism in a patient with cirrhosis and ascites. Arch Intern Med 146:2407-2408, 1986.
65. Yoshimo A, Amerian R, Brautbar N. Hyporeninemic hypoaldosteronism in sickle cell diseaase. Nephron 31:242-244, 1982.
66. Kalin MF, Poretsky L. Seres DS, et al. Hyporeninemic hypoaldosteronism associated with acquired immune deficiency syndrome. Am J Med 82:1035-1038, 1987.
67. Soublier M, Deteix P, Derray G, set al. Manifestation rénales du syndrome POEMS. Nephrologie 15:335-338, 1994.
68. Oster JR, Perez GO, Rosen MS. Hyporeninemic hypoaldosteronism after chronic sodium bicarbonate abuse. Arch Intern Med 136:1179-1180, 1976.
68.1. Muto S, Akai Y, Ono S, et al. Selective hypoaldosteronism due to combined defects of the conversion from inactive renin to active renin and the aldosterone biosynthesis from corticosterone. Nephron 88:247-253, 2001.
68.2. Onozaki A, Katoh T, Watanabe T, et al. Hyporeninemic hypoaldosteronism associated with Sjögren’s syndrome. Am J Med 112:245-246, 2002.
69. Masud T, Wincour P, Clarke F. Reversible hyporeninemic hypoaldosteronism and lifethreatening cardiac dysrhythmias: the interaction of non-steroidal anti-inflammatory drugs and autonomic dysfunction. Postgrad Med J 69:593-594, 1993.
70. Herring P, Grabensee B. Influence of cyclosporin A on renal tubular function after kidney transplantation. Nephron 59:66-70, 1993.
71. Motoo Y, Sawabu N, Ikeda K, et al. Long-term follow-up of mitomycin C nephropathy. Intern Med 33:180-184, 1994.
72. Feuerstein BL, Lebpwitz MR, Blumenthal SA, et al. Severe hyperkalemia in two patients with diabetes after cosyntropin administration. J Diabetes Complecations 6:203-206, 1973.
73. Sunderlin FS, Anderson GH, streeten DHP, et al. The renin-angiotensin-aldosterone system in diabetic patients with hyperkalemia. Diabetes 30:335-340, 1981.
74. Defronzo R. Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int 17:118-134, 1980.
75. Perez GO, Lespier LE, Oster JR, et al. Effects of alteration of sodium intake in patients with hyporeninemic hypoaldosteronism. Nephron 18:249-265, 1977.
76. Tuck ML, Sambhi MP, Levin L. Hyporeninemic hypoaldosteronism in diabetes mellitus: studies of the autonomic nervous system's control of renin release. Diabetes 28:237-241, 1979.
77. Delevia A, Christlieb AR, Melby JC, et al. Big renin and biosynthetic defect of aldosterone in diabetes mellitus. N Engl J Med 295:639-43, 1976.
78. Oster JA, Whorton AR, Gerkens JH, et al. The participation of prostaglandins in the control of renin release. Fed Proc 38:72-74, 1979.
79. Nadler JL, Lee FO, Hsuch W, et al. Evidence of prostacyclin deficiency in the syndrome of hyporeninemic hypoaldosteronism. N Engl J Med 314:1015-1020, 1986.
80. Fitzgerald GA, Hossman V, Himmerich W, et al. The renin-kallikrein-prostaglandin system: plasma active and inactive renin and urinary kallikrein during prostacyclin infusion in man. Prostaglandins Med 5:445-456, 1980.
81. Hambling C, Jung RT, Browning MC, et al. Primary hyperaldosteronism-evaluation of procedures for diagnosis and localization. Q J Med 86:383-392, 1993.
82. Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two major subtype. Arch Intern Med 153:2125-2129, 1993.
83. Ulick S, Wang JZ, Morton DH. The biochemical phenotypes of two inborn errors in the biosynthesis of aldosterone. J Clin Endocrinol Metab 74:1415-1420, 1992.
84. Mitsuuchi Y, Kawamoto T, Miyahara K, et al. Congenitally defective aldosterone biosynthesis in humans: inactivation of the P-450C18 gene (CYP11B2) due to nucleotide deletion in CMO I deficient patients. Biochem Biophys Res Commun 190:864-869, 1993.
85. Shizuta Y, Kawamoto T, Mitsuuchi Y, et al. Inborn errors of aldosterone biosynthesis in humans. Steroid 60:1521, 1995.
86. Geley S, Johrer K, Peter M, et al. Amino acid substitution R384P in aldosterone synthase causes corticosterone methyloxidase type I deficiency. J Clin Endocrinol Metab 80:424-429, 1995.
87. Pascoe L, Vrunow KM, Slutsker L, et al. Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency. Proc Natl Acad Sci USA 89:4996-5000, 1992.
88. Zhang G, Rodriguez H, Fardella CE, et al. Mutation T318M in the CYP11B2 (aldosterone synthase) causes corticosterone methyloxidase II deficiency. Am J Hum Genet 57:1037-1043, 1995.
88.1. Kuribayashi I, Kuge H, Santa RJ, et al. A missense mutation (GCC［435Gly］→AGC［Ser］) on exon 8 of the CYP11B2 Gene inherited in Japanese patient with congenital hypoaldosteronism. Horm Res 60:255-26, 2003.
88.2 Williams TA, Muratero P, Bosio M, et al. A particular phenotype in a girl with aldosterone synthase deficiency. J Clin Endocrinol Metab 89:3168-3172, 2004.
89. Rösler A. The natural history of salt-wasting disorders of adrenal and renal origin. J Clin Endocrinol Metab 59:689-700, 1984.
90. Petr M, Partsch CJ, Sillel WG. Multisteroid analysis in children with terminal aldosterone biosynthesis defects. J Clin Endocrinol Metab 80:1622-1627, 1995.
91. Ulick S. Editorial: Cortisol as mineralocorticoid. J Clin Endocrinol Metab 81:1307-1308, 1996.
92. O'Kelly R, Magee F, McKenna TJ. Routine heparin therapy inhibits adrenal aldosterone production. J Clin Endocrinol Metab 53:108-112, 1983.
93. Squeira SJ, McKenna TJ. Chlorbutol, a new inhibitor of aldosterone biosynthesis identified during examination of heparin effect on aldosterone production. J Clin Endocrinol Metab 63:780-784, 1986.
94. Zipser RD, Davenport MW, Martin KL, et al. Hyperreninemic hypoaldosteronism in the critically ill: a new entity. J Clin Endocrinol Metab 53:867-873, 1981.
95. Davenport MW, Zipser RD. Association of hypotention with hyperreninemic hypoaldosteronism in the critically ill patients. Arch Intern Med 143:735-737, 1983.
96. Cheek DB, Perry J. A salt wasting syndrome in infancy. Arch Dis Child 33:252-256, 1958.
97. Speiser PW, Stoner E, New MI. Pseudohypoaldosteronism: A review and report of two cases. In: Chrousos GP, Loriaux DI, Lipsett MB, eds. Mechanisms and clinical aspects of steroid hormone resistance. New York: Plenum Press, pp173-195, 1986.
98. Strautnieks SS, Thompson RJ, Gardiner RK, et al. A novel splice-site mutation in the ? subunit of the epithelial sodium channel gene in three pseudohypoaldosteronism type 1 families. Nature Genet 13:248-250, 1996,
99. Geller DS, Rodriguez-Soriano J, Vallo Boado A, et al. Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. Nature Genet 19:279-281, 1998.
100. Tajima T, Kitagawa H, Yokoya S, et al. A novel missense mutation of mineralocorticoid receptor gene in one Japanese family with a renal form of pseudohypoaldosteronism type 1. J Clin Endocrinol Metab 856:4690-4694, 2000.
101. Arai K, Tsigos C, Suzuki Y, et al. Physiological and molecular aspects of mineralocorticoid receptor action on pseudohypoaldosteronism: A responsiveness test and therapy. J Clin Endocrinol Metab 79:1019-1023, 1994.
102. Zennaro MC, Borensztein P, Jeunemaitre X, et al. No alteration in the primary structure of the mineralocorticoid receptor in a family with pseudohypoaldosteronism. J Clin Endocrinol Metab 79:32-38, 1994.
103. Komesaroff PA, Verity K, Fuller PJ. Pseudohypoaldosteronism: Molecular characterization of the mineralocorticoid receptor. J Clin Endocrinol Metab 79:27-31, 1994.
104. Corvol P, Funder J. Editorial: The enigma of pseudohypoaldosteronism. J Clin Endocrinol Metab 79:25-26, 1994.
105. Arai K, Tsigos C, Suzuki Y, et al. No apparent mineralocorticoid receptor defect in a series of sporadic cases of pseudohypoaldosteronism. J Clin Endocrinol Metab 80:814-817, 1995.
106. Arai K, Zachman K, Shibasak,i T et al. Polymorphisms of amiloride-sensitive sodium channel subunits in five sporadic cases of pseudohypoaldosteronism: do they have pathologic potential? J Clin Endocrinol Metab 84:2434-2437, 1999;
107. Viemann M, Peter M, López-Siguero JP, et al. Evidence for genetic heterogeneity of pseudohypoaldosteronism type 1: identification of a novel mutation in the human mineralocorticoid receptor in one sporadic case and no mutations in two autosomal dominant kindreds. J Clin Endocrinol Metab 86:2056-2059, 2001.
107.1. Riepe FG, Krone N, Mortot M, et al. Identification of a novel mutation in the human mineralocorticoid receptor gene in a German family with autosomal-dominant pseudohypoaldosteronism type 1: further evidence for marked interindividual clinical heterogeneity. J Clin Endocrinol Metab 88:1683-1686, 2003.
107.2. Nyström AM, Bondeson ML, Sakane N, et al. A novel nonsense mutation of the mineralocorticoid receptor gene in a Swedish family with pseudohypoaldosteronism type 1 (PHA1). J Clin Endocrinol Metab 89:227-231, 2004.
107.3. Autosomal-dominant pseudohypoaldosteronism type 1 in a Turkish family is associated with a novel nonsense mutation in the human mineralocorticoid receptor gene. J Clin Endocrinol Metab 89:2150-2152, 2004.
107.4. Sartorato P, Lapeyraque AL, Armanini D, et al. Different inactivating mutation of the mineralocorticoid receptor in fourteen families affected by type I pseudohypoaldosteronism. J Clin Endocrinol Metab 88:2508-2517, 2003.
108. Oberfield SE, Levine LS, Carey RM, et al. Pseudohypoaldosteronism: multiple target organ unresponsiveness to mineralocorticoid hormones. J Clin Endocrinol Metab 48:228-234, 1977.
109. Schaedel C, Marthinsen L, Kristoffersson AC, et al. Lung symptoms in pseudohypoaldosteronism type 1 are associated with deficiency of the ?-subunit of the epithelial sodium channel. J Pediatr 135:739-745, 1999.
110. Gründer S, Firsov D, Chang SS, et al. A mutation causing pseudohypoaldosteronism type 1 identifies a conserved glycine that is involved in the gating of the epithelial sodium channel. EMBO J 16:899-907, 1997.
110.1. Saxena A, Hanukoglu I, Saxena D, et al. Novel mutations responsible for autosomal recessive multisystem pseudohypoaldosteronism and sequence variants in epithelial sodium channel -, -, and -subunit genes. J Clin Endocrinol Metab 87:3344-3350, 2002.
111. Adachi M, Tachibana K, Asakura Y, et al. Compound heterozygous mutations in the ? subunit gene of ENaC (1627delG and1570-1G®A) in one sporadic Japanese patient with a systemic form of pseudohypoaldosteronism type 1. J Clin Endocrinol Metab 86:9-12, 2001.
111.1. Arai K, Nakagomi Y, Iketani M, et al. Functional polymorphisms in the mineralocorticoid receptor and amirolide-sensitive sodium channel genes in a patients with sporadic pseudohypoaldosteronism. Hum Genet 112:91-97, 2003.
112. Warnock DG. Accessory factors and the regulation of epithelial sodium channel activity (Editorial). J Clin Invest 103:593, 1999.
113. Kajiwara K, Berson EL, Dryja T. Digenic retinitis pigmentosa due to mutations at the unlinked peripherin/RDS and ROM1 loci. Science 264:1604-1608, 1944.